BACKGROUND: High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV) therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated the effects of switching antibiotic administration route in Japan, especially for linezolid. This study evaluated an IV-to-oral antibiotic switching program for linezolid treatment at a university hospital in Japan. METHODS: In a retrospective cohort study of 73 patients, we assessed the efficacy and safety of IV-to-oral linezolid therapy (n = 21 patients) compared with IV therapy alone (n = 52 patients). RESULTS: Duration of linezolid treatment, changes in C-reactive protein or platelet count from baseline, re-administration of anti-methicillin-resistant Staphylococcus aureus agent within 90 days of discharge, and mortality within 28 days of discharge were not significantly different between the two groups. CONCLUSIONS: An IV-to-oral switching program could reduce the duration of IV linezolid therapy without worsening clinical outcomes in Japanese patients receiving linezolid therapy.
BACKGROUND: High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV) therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated the effects of switching antibiotic administration route in Japan, especially for linezolid. This study evaluated an IV-to-oral antibiotic switching program for linezolid treatment at a university hospital in Japan. METHODS: In a retrospective cohort study of 73 patients, we assessed the efficacy and safety of IV-to-oral linezolid therapy (n = 21 patients) compared with IV therapy alone (n = 52 patients). RESULTS: Duration of linezolid treatment, changes in C-reactive protein or platelet count from baseline, re-administration of anti-methicillin-resistant Staphylococcus aureus agent within 90 days of discharge, and mortality within 28 days of discharge were not significantly different between the two groups. CONCLUSIONS: An IV-to-oral switching program could reduce the duration of IV linezolid therapy without worsening clinical outcomes in Japanese patients receiving linezolid therapy.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: T Ichie; D Suzuki; K Yasui; H Takahashi; M Matsuda; H Hayashi; Y Sugiura; T Sugiyama Journal: J Clin Pharm Ther Date: 2015-03-02 Impact factor: 2.512
Authors: I Starakis; D Karravias; C Asimakopoulos; P Kolaras; P Nikolaidis; N Harlaftis; A Skoutelis; H Bassaris Journal: Int J Antimicrob Agents Date: 2003-01 Impact factor: 5.283
Authors: Peter Davey; Erwin Brown; Lynda Fenelon; Roger Finch; Ian Gould; Alison Holmes; Craig Ramsay; Eric Taylor; Phil Wiffen; Mark Wilcox Journal: Emerg Infect Dis Date: 2006-02 Impact factor: 6.883
Authors: Arthur R H van Zanten; Peter M Engelfriet; Karin van Dillen; Miriam van Veen; Mark J C Nuijten; Kees H Polderman Journal: Crit Care Date: 2003-10-14 Impact factor: 9.097